Moleculin Biotech (MBRX) Earning Somewhat Favorable Media Coverage, Report Shows
Media headlines about Moleculin Biotech (NASDAQ:MBRX) have been trending somewhat positive recently, Accern Sentiment reports. Accern rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Moleculin Biotech earned a news impact score of 0.24 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.8636259371315 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:
- Positive Clinical Trial Developments Advance Forward for Biotech Sector Heading Into the New Year (prnewswire.co.uk)
- MOLECULIN BIOTECH, INC. : Other Events, Financial Statements and Exhibits (form 8-K) (4-traders.com)
- Moleculin’s WP1066 Drug gets FDA Brain Tumor IND Clearance (finance.yahoo.com)
- Why Moleculin Biotech Inc’s (MBRX) Ownership Structure Is Important (finance.yahoo.com)
Shares of Moleculin Biotech (MBRX) traded up $0.07 during trading on Tuesday, hitting $1.82. The stock had a trading volume of 340,800 shares, compared to its average volume of 1,277,545. Moleculin Biotech has a fifty-two week low of $0.71 and a fifty-two week high of $3.75.
Moleculin Biotech (NASDAQ:MBRX) last announced its quarterly earnings results on Tuesday, November 14th. The company reported ($0.14) earnings per share (EPS) for the quarter.
Separately, ValuEngine upgraded Moleculin Biotech from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.dailypolitical.com/2017/12/05/moleculin-biotech-mbrx-earning-somewhat-favorable-media-coverage-report-shows.html.
About Moleculin Biotech
Moleculin Biotech, Inc is a preclinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML).
Receive News & Ratings for Moleculin Biotech Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech Inc and related companies with MarketBeat.com's FREE daily email newsletter.